Molecular Partners AG (MOLN)
NASDAQ: MOLN · Real-Time Price · USD
3.240
-0.240 (-6.90%)
Nov 3, 2026, 8:10 AM EST - Market open
Molecular Partners AG Market Cap
Molecular Partners AG has a market cap or net worth of $121.01 million as of November 3, 2026. Its market cap has decreased by 10.38% in one year.
Market Cap
121.01M
Enterprise Value
54.18M
1-Year Change
-10.38%
Global Rank
n/a
Country Rank
n/a
Category
ChartMarket Cap Chart
Since the IPO on June 16, 2021, Molecular Partners AG's market cap has decreased from $683.35M to $121.01M, a decrease of -82.29%. That is a compound annual growth rate of -27.49%.
| Date | Market Cap | % Change |
|---|---|---|
| Nov 3, 2026 | 121.01M | -24.43% |
| Dec 30, 2025 | 160.13M | -2.96% |
| Dec 30, 2024 | 165.01M | 22.94% |
| Dec 29, 2023 | 134.22M | -38.09% |
| Dec 30, 2022 | 216.81M | -65.56% |
| Dec 30, 2021 | 629.47M | -7.89% |
| Jun 16, 2021 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Protara Therapeutics | 146.56M |
| Satellos Bioscience | 145.06M |
| Compass Therapeutics | 141.64M |
| Atrium Therapeutics | 141.46M |
| Jyong Biotech | 139.56M |
| NovaBridge Biosciences | 138.62M |
| Spruce Biosciences | 133.33M |
| Innate Pharma | 131.41M |